On May 18, 2009, Atomic Energy of Canada Limited (AECL) announced that the 52-year-old National Research Universal (NRU) reactor at Chalk River was out of service after detection of a heavy-water leak in the containment vessel, and they would not be able to supply several radioisotopes, most notably molybdenum 99 ( 99 Mo) used in the manufacture of 99m Tc generators. Because approximately 40%e50% of the world's supply of 99 Mo was produced at the NRU reactor, this sudden loss threatened the provision of nuclear medicine studies to millions of patients around the world. There are approximately 30,000 nuclear medicine procedures performed every week in Canada at more than 200 nuclear medicine facilities and more than 15,000,000 every year in the United States. More than 70% of those procedures use 99m Tc radiopharmaceuticals. By the end of May 2009, it became obvious that this would not be a shortterm problem, and, in August, the AECL announced that the NRU reactor would not return to service before Spring 2010. To further compound a bad situation, the second largest supplier of 99 Mo in the world, the HFR-Petten reactor in the Netherlands was shut down for a 4-week routine maintenance in late July, which resulted in even more marked shortages into late August.
Unfortunately, this was not the first prolonged shutdown of the NRU reactor. In late 2007, a dispute between the Canadian Nuclear Safety Commission (CNSC) and AECL caused an extended outage that eventually resulted in an act of Parliament (Bill C-38) to allow restarting of the NRU reactor. Subsequently, several reports examined the issues and problems surrounding those events, and recommendations were made to prevent a similar occurrence. A June 2008 report by Talisman International [1] laid the blame on a culture of informality and interactions that were ''expert based'' and not ''process based.'' A separate report of the Ad Hoc Health Experts Working Group on Medical Isotopes to Health Canada submitted in May 2008 recommended a made-in-Canada solution that included replacement of the NRU reactor and diversification of the 99m Tc generator supply in Canada [2] .
In recent years, almost all 99 Mo for medical uses has been produced by irradiating uranium targets in just 5 reactors [3] .The largest and most productive reactors have been the Canadian NRU reactor and the Dutch HFR-Petten reactor. These 2 reactors accounted for 60%-80% of worldwide production, although the NRU reactor alone was capable of supplying up to 80% of the world's supply of 99 Mo. Much smaller amounts are produced at reactors in Belgium, France, and South Africa (the Safari reactor). All of these reactors are aging and are at or even beyond their projected life span, with the Safari reactor being the newest, at 43 years of age. For some time, Canada has been preeminent in the world's supply of 99 Mo by using the NRU reactor. In 1991, MDS purchased Nordion from the Canadian government, and a secure long-term medical isotope supply was considered a key component of that purchase. Nordion acts as the processing facility for purification of 99 Mo from the NRU reactor and sells the 99 Mo to the generator manufacturers based in the United States (currently Covidien in St Louis, MO, and Lantheus in Boston, MA) who supply the entire North American market. The radiopharmaceutical market is relatively small, and, because the production of 99 Mo has often benefited from direct government support for research reactor operations, there has been little impetus or profit for other suppliers to get into the business of 99 Mo production. As the NRU reactor aged, it was obvious by the mid1990s that a replacement would be necessary. In 1996, MDS Nordion contracted with AECL to construct 2 nuclear reactors and a processing facility at Chalk River (the MAPLE project) to be operational in 2000. This effectively closed the door to consideration of other proposals at the time, including proposals that would have shifted production for the American market to the United States. Unfortunately, the MAPLE reactors fell behind schedule and the costs more than doubled, to $350 million. After years of delays, an updated new agreement was reached in 2006 whereby AECL would bring the MAPLE reactors on line by October 2008 and AECL would supply isotopes to Nordion for 40 years. The MAPLE reactors have been plagued by an unexplained positive power coefficient of reactivity (PCR) that has prevented their licensing by CNSC, and, after much investigation and examination of proposed solutions, AECL and the Government of Canada announced the discontinuation of the MAPLE project on May 16, 2008. There has been much debate surrounding this issue, with a number of scientists stating that it is safe to run the MAPLE reactors but with AECL insisting that the positive PCR presents a ''potentially insurmountable hurdle to safely commissioning the MAPLE reactors as currently designed.'' On July 9, 2008, MDS Nordion filed suit against AECL and the Government of Canada, seeking $1.6 billion in damages for negligence and breach of contract [4] .
Currently,
99
Mo production uses nuclear bomb grade highly enriched uranium (HEU) targets that contain about 93% uranium 235. HEU is produced in the United States and has been made available as a target material through a loop hole in nuclear nonproliferation agreements. With the continued proliferation of nuclear weapons and terrorism in recent years, the United States has made it clear that it will not supply HEU outside the United States for much longer and has encouraged 99 Mo suppliers to switch their production to the use of low enriched uranium (LEU) targets that contain less than 20% uranium 235. The switch to LEU targets may be expensive and will likely require more suppliers because of the lower 99 Mo yields when bombarding LEU. Under the Energy Policy Act of 2005, the US Secretary of Energy contracted with the National Academy of Sciences to conduct a study on the elimination of HEU targets. This review was also to evaluate the demand and availability of medical isotopes in regular domestic use and recommend various solutions to the problem of repeated shortages. The Committee on Medical Isotope Production Without Highly Enriched Uranium included 3 Canadian experts in the field. Their report, issued in January 2009, concluded that conversion to LEU targets was possible, although may be more costly than anticipated and may require government subsidies [5] . This report also discusses a number of alternative sources of the 99 Mo supply. It was obvious to the committee that the supply of 99 Mo was tenuous at best and that reliability of supply was more of an immediate issue to patient and public welfare than conversion to LEU, a prediction that was sadly proven to be true only a few months later when the NRU reactor was shutdown.
There is no quick fix to the problem that nuclear medicine finds itself in today, but a number of initiatives in both the United States and Canada are underway to find solutions. The major commercial suppliers of 99m Tc generators, Covidien and Lantheus, have worked tirelessly to try and maximize the availability of generators in Canada, the United States, and Europe. Some of the lessons of communication and cooperation learned at the time of the last crisis in late 2007 have helped nuclear medicine suppliers and facilities to maximize the availability of radioisotopes for patient studies. In early July 2009, Lantheus received speedy approval from both Health Canada and the U.S. Food and Drug Administration for the use of 99 Mo from the new Australian Nuclear Science and Technology Organisation OPAL reactor that uses LEU fuel and targets. Unfortunately, this reactor was originally intended only to provide 99 Mo for the local Australia and New Zealand markets, and is only capable of providing a fraction of current shortfalls in the world supply. Covidien with Babcock and Wilcox (a large nuclear industry company in the United States) entered into an agreement in January 2009 to develop a new production system by using a reactor in which LEU is used as both fuel and target in an aqueous solution, with 99 Mo being extracted from the liquidphase fuel [6] . This is envisioned as a low-power reactor that produces minimal radioactive waste. However, even with several reactors of this size, it is anticipated that they would only supply 50% of the current US demand, and the project is several years from being operational. Recently, MDS Nordion announced an agreement to study the feasibility of obtaining 99 Mo from the Karpov Institute of Physical Chemistry in Moscow, which currently provides most of the 99m Tc generators for the domestic Russian market. It is estimated that once tooled up, they might be able to supply an additional 10%-15% of the world market.
A report of the Society of Nuclear Medicine (SNM) Isotope Availability Task Force issued, in updated draft form, on February 23, 2009, identified several existing reactors which could be used to supply 99 Mo [7] . The University of Missouri Research Reactor (MURR), with only minor changes, could supply 50% of the US market and may be the easiest current alternative. However, it will take 3e4 years for MURR to build the appropriate processing facilities to handle this volume. A proposal to develop 99 Mo production by using LEU solution targets at the University of California at Davis in the McClellan Nuclear Radiation Center reactor could also reach the commercial production stage in 3-4 years. Several other US Department of Energy (DOE) and university research reactors could supply much of the US demand for 99 Mo but would require major construction or development projects and/or significant changes in their current missions and approvals and licensing and would require more than 5 years to implement.
On July 10, 2009, a White Paper on the supply of 99 Mo was published by a coalition of the SNM and 8 other professional organizations in the United States [8] . The coalition strongly advocated a domestic production capability that would ensure availability of nuclear medicine studies for their patients, even in the unlikely event of a complete closing of the US border to any radioactive shipments. They argued for a public-private partnership to develop domestic production of 99 Mo as quickly as possible and particularly highlighted the MURR and Babcock and Wilcox options. The need for co-operation from regulatory authorities was also discussed, and they strongly urged that any change from HEU to LEU targets be undertaken only if patient needs are not compromised and only once the technology has been proven and financial and regulatory support is in place.
There seems little doubt now that the United States will proceed as rapidly as possible to develop a made-in-the-US approach that will ensure adequate supplies of 99 Mo for American patients. On July 21, Representatives Edward Markey and Fred Upton introduced the American Medical Isotopes Production Act of 2009 (H.R. 3276) in the House of Representatives in the US Congress [9] . This bill will provide the resources and authority to the DOE to bring domestic production of 99 Mo in the United States online as soon as possible. The bill allocates $163 million over 5 years, which fully funds the DOE cost projections for creating a robust domestic production capacity for 100% of their 99 Mo needs. Furthermore, the bill will end all exports of HEU within 7 years (2017) and asks the Nuclear Regulatory Commission to review and report on all previous HEU exports from the United States. The licensed use of HEU targets in the United States will be allowed, but the programs must actively support the development of alternative targets. Finally, the bill mandates the National Academy of Sciences to issue a report within 5 years on all 99 Mo production facilities and to assess the progress on eliminating HEU targets worldwide. This bill is strongly supported by the SNM and a coalition of other organizations as well as the 2 main commercial suppliers of 99m Tc generators. On the Canadian side of the border, there are attempts being made by the government to both develop alternative supplies of 99 Mo and foster alternatives to 99 Mo99m Tc based radiopharmaceuticals by switching to the use of other isotopes, including cyclotron-produced isotopes such as thallium 201 and positron emitters used in positron emission tomography studies. The Canadian Association of Nuclear Medicine and Canadian Medical Association have made a number of presentations to various government agencies and departments outlining the efforts being made in Canadian nuclear medicine facilities to maintain services for patients despite the shortages. This has included rescheduling patients to best fit the availability of 99m Tc generators, which has occasionally meant more overtime and weekend appointments. As a whole, these changes and day-to-day flexibility have meant that patient nuclear medicine services have been maintained, especially for urgent studies, and that wait lists have not grown substantially in most provinces, although there are some persisting disparities of supply in certain areas of the country.
Both the Canadian Ministry of Natural Resources and Ministry of Health have been very active in dealing with the current crisis, by building on strategies developed during the last shortage. The government has been at the forefront of international efforts to effect solutions and coordinate radioisotope production through the Nuclear Energy [10] . A number of proposals have already been made public.
MDS Nordion submitted a proposal to the expert committee to complete and bring into service the MAPLE reactors within 24 months by using the assistance of the South African Nuclear Energy Corporation, which operates the SAFARI reactor. It is argued that that use of different computer codes to model the reactor performance might resolve the discrepancy between the models and the actual reactor performance and that this would allow licensing of the reactors by CNSC [11] . Previous calls by MDS Nordion to complete the MAPLE project have been met by AECL claims that resolution of the PCR problem in the reactors might be impossible and that a best-case scenario would still be at least 5e6 more years. As well, proposals to redesign and replace the cores of the MAPLE reactors (costs estimated by MDS Nordion at tens of millions of dollars) have been countered by AECL statements that this would require 7e10 years to complete.
The Province of Saskatchewan in partnership with the University of Saskatchewan has also submitted a proposal to the panel. As the world's largest producer of uranium and home of the Canadian Light Source synchrotron, Saskatchewan has proposed a new research reactor, the Canadian Neutron Source facility, to serve the needs for both production of medical isotopes and for research in neutronbased science. Total costs are estimated at $500e$750 million, with completion by 2016.
There are a number of nonreactor-based proposals. Advanced Cyclotron Systems Incorporated of British Columbia proposed producing 99m Tc directly by use of 24 MeV cyclotrons by using enriched molybdenum 100 as the target material. Estimates are that, for a 6-hour irradiation, almost 2 TBq of 99m Tc could be produced. Although this nongenerator solution requires daily production, being able to produce 99m Tc several times a day could meet the needs of nearby regional centers and allow for scarce generators to be used in more distant locations. Another proposal is an accelerator-based plan from the Prairie Isotope Production Enterprise at the University of Winnipeg that might be able to supply Canada's needs, for a total investment of $35 million within 3 years.
One of the most innovative suggestions in the recent past has come from the TRIUMF facility in Vancouver. Even before the current crisis, TRIUMF proposed a project to examine the production of 99 Mo by photon fission of uranium 238 by using photons from an electron accelerator [12] . Unfortunately, 99 Mo yields are low, which necessitates multiple units to supply the world's needs, and the technology is as yet unproven. In April 2009, MDS Nordion and TRIUMF signed an agreement to study the feasibility of producing photon fission 99 Mo for the global isotope market by building on the 30-year university-industry relationship between them. A formal submission by the 2 partners to the expert panel proposes the use of superconducting radiofrequency electron accelerators to achieve technical demonstration of principle of the method by 2012 and commercial production by 2015. It is projected that one such system could supply 100% of the Canadian domestic market for 99 Mo and would cost approximately $50 million. It took a few years to reach the situation we find ourselves in today, and it will be several more years to reach stability again. Many lessons have been learned, not least of which is to ensure a diversity of supply that will be prevent any future recurrences. Although 99 Mo generators and thus 99m Tc radiopharmaceuticals were relatively cheap in the past, we are likely to see significant increases in the cost of 99m Tc products in the future, regardless of the solutions developed. Over the last few months, we have all witnessed an extraordinary degree of cooperation and understanding between commercial suppliers, government agencies and ministries, hospitals, nuclear medicine facilities, physicians, and even our patients. This has helped to ensure that the provision of nuclear medicine services continues through this current shortage with as little disruption as possible for our patients. Although the current situation may continue for another 6e9 months, we look forward to both medium-term solutions next year (restarting the NRU reactor) and longterm solutions for the isotope supply issues as they evolve over the next 5e10 years.
